公开(公告)号：US20050143588A1

公开(公告)日：2005-06-30

申请号：US10851270

申请日：2004-05-20

Applicant: Andrew Heaton ,  Naresh Kumar

Inventor： Andrew Heaton ,  Naresh Kumar

IPC: C07B61/00 ,  C07D311/36 ,  C07D311/38 ,  C07D311/56 ,  C07D311/58 ,  C07D311/74

CPC classification number: C07D311/56 ,  C07D311/36 ,  C07D311/38

Abstract: Methods for the hydrogenation of isoflavones are described which provide access to workable quantities of isoflavan-4-ols, isoflav-3-enes, and isoflavans. The isoflavone derivatives can be obtained in high purity and in near quantitative yields whilst employing pharmaceutically acceptable reagents and solvents.

Abstract translation: 描述了异黄酮氢化方法，其提供了可使用量的异黄烷-4-醇，异氟烷-3-烯和异构体。 异黄酮衍生物可以以高纯度和接近定量的产率获得，同时使用药学上可接受的试剂和溶剂。

公开(公告)号：US06331638B1

公开(公告)日：2001-12-18

申请号：US09412455

申请日：1999-10-04

Applicant: B. Vijay Raghavan ,  K. V. Ramana ,  Brij Khera ,  Naresh Kumar

Inventor： B. Vijay Raghavan ,  K. V. Ramana ,  Brij Khera ,  Naresh Kumar

IPC: C07D491052

CPC classification number: C07D491/04

Abstract: A process for the preparation of the esters of 1,8-disubstituted-1,3,4,9-tetrahydropyrano (3,4-b)-indole-1-acetic acid is delineated.

Abstract translation: 描述了制备1,8-二取代-1,3,4,9-四氢吡喃（3,4-b） - 吲哚-1-乙酸的酯的方法。

公开(公告)号：US5696275A

公开(公告)日：1997-12-09

申请号：US265308

申请日：1994-06-24

Applicant: Jag Mohan Khanna ,  Naresh Kumar ,  Brij Khera ,  Purna Chandra Ray

Inventor： Jag Mohan Khanna ,  Naresh Kumar ,  Brij Khera ,  Purna Chandra Ray

IPC: C07D307/52

CPC classification number: C07D307/52

Abstract: A process for the manufacture of pharmaceutical grade ranitidine base(N-�2-���5-(Dimethylamino)methyl!-2-furanyl!methyl!thio!ethyl-N'-methyl-2-nitro-1, 1-ethenediamine), is described. In-vitro and in-vivo pharmacological studies and acute toxicity studies indicate that it is as active and as safe as Form 2 ranitidine hydrochloride.

Abstract translation: 制备药物级雷尼替丁碱（N- [2 - [[[5-（二甲基氨基）甲基] -2-呋喃基]甲基]硫基]乙基-N'-甲基-2-硝基-1,1- 乙烯二胺）。 体外和体内药理学研究和急性毒性研究表明，它与盐酸盐酸雷尼替丁的活性和安全性一样。

公开(公告)号：US08679557B2

公开(公告)日：2014-03-25

申请号：US12529015

申请日：2008-02-27

Applicant: Suresh Kumar Gupta ,  Shyam Sunder Agrawal ,  Renu Agrawal ,  Sushma Srivastava ,  Ankita Nagpal ,  Naresh Kumar ,  Rohit Saxena ,  Sateesh Kumar Chauhan ,  Deepak Bahri

Inventor： Suresh Kumar Gupta ,  Shyam Sunder Agrawal ,  Renu Agrawal ,  Sushma Srivastava ,  Ankita Nagpal ,  Naresh Kumar ,  Rohit Saxena ,  Sateesh Kumar Chauhan ,  Deepak Bahri

IPC: A61K36/906 ,  A61K36/00

CPC classification number: A61K36/53 ,  A61K36/81 ,  A61K36/889 ,  A61K36/9066

Abstract: The present invention relates to a synergistic herbal composition for lowering the intra ocular pressure in different types of glaucoma and process for the preparation of the same in pharmaceutically acceptable dosage forms.

Abstract translation: 本发明涉及用于降低不同类型青光眼的眼内压的协同草药组合物及其在药学上可接受的剂型中的制备方法。

公开(公告)号：US08126958B2

公开(公告)日：2012-02-28

申请号：US13189524

申请日：2011-07-24

Applicant: Naresh Kumar ,  Robert Perry

Inventor： Naresh Kumar ,  Robert Perry

IPC: G06F15/16 ,  G06F15/173 ,  H04N7/16 ,  H04N7/173

CPC classification number: H04L12/14 ,  G06F11/2033 ,  G06F11/2038 ,  G06F11/2041 ,  H04L12/1403 ,  H04L69/40 ,  H04M15/70 ,  H04M15/74 ,  H04M2215/70 ,  H04M2215/709

Abstract: A determination is made whether a first application server of a group of N application servers, N being at least two, is a coordinator of the group. Responsive to determining that the first application server is the coordinator of the group, a connection to a billing system is established, via a terminal server, by the first application server. A determination is made whether a second application server of the group of N application servers is the coordinator of the group. Responsive to determining that the second application server is not the coordinator of the group, a periodic check is made whether the second application server of the group of N application servers is the coordinator of the group. The second application server may later be determined to be the coordinator of the group, when the first server experiences difficulty. Once it is determined that the second application server now is the coordinator of the group, a connection is established to the billing system, via the terminal server, by the second application server.

Abstract translation: 确定一组N个应用服务器的第一应用服务器是否为该组的协调器，N至少为两个。 响应于确定第一应用服务器是该组的协调器，通过终端服务器由第一应用服务器建立与计费系统的连接。 确定N个应用服务器组的第二应用服务器是否是该组的协调器。 响应于确定第二应用服务器不是组的协调器，定期检查N个应用服务器组中的第二应用服务器是否是该组的协调器。 当第一服务器遇到困难时，可以将第二应用服务器确定为该组的协调器。 一旦确定第二应用服务器现在是组的协调器，则通过第二应用服务器经由终端服务器向计费系统建立连接。

公开(公告)号：US20110046722A1

公开(公告)日：2011-02-24

申请号：US12528208

申请日：2008-02-29

Applicant: Andrew Heaton ,  Naresh Kumar ,  Catherine Walker

Inventor： Andrew Heaton ,  Naresh Kumar ,  Catherine Walker

IPC: A61F2/82 ,  C07D498/04 ,  A61K31/5365 ,  A61P9/00 ,  A61P29/00 ,  A61P39/06

CPC classification number: C07D498/04

Abstract: The invention provides oxazinyl isoflavonoid compounds and compositions containing same, methods for their preparation and their use as therapeutic agents particularly as cardioprotective, anti-inflammatory, anti-oxidant and chemotherapeutic agents.

Abstract translation: 本发明提供了恶嗪基异黄酮化合物和含有其的组合物，其制备方法及其作为治疗剂的用途，特别是作为心脏保护剂，抗炎剂，抗氧化剂和化学治疗剂。

公开(公告)号：US20100144801A1

公开(公告)日：2010-06-10

申请号：US12443838

申请日：2007-10-02

Applicant: Naresh Kumar ,  Jaskiran Kaur ,  Abhijit Ray ,  Suman Gupta ,  Shivani Malhotra ,  Rajkumar Shirumalla

Inventor： Naresh Kumar ,  Jaskiran Kaur ,  Abhijit Ray ,  Suman Gupta ,  Shivani Malhotra ,  Rajkumar Shirumalla

IPC: A61K31/44 ,  C07D213/55 ,  C07D233/54 ,  A61K31/4164 ,  A61P11/00 ,  A61P13/00 ,  A61P1/00 ,  A61P3/00

CPC classification number: C07D233/64 ,  C07D211/70 ,  C07D213/30

Abstract: The present invention generally relates to muscarinic receptor antagonists of formula I, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors. Formula (I) wherein Het: is heterocyclyl or heteroaryl X: O, S or NR1 and the other substituents are defined as in the claims.

Abstract translation: 本发明一般涉及式I的毒蕈碱受体拮抗剂，其可用于治疗通过毒蕈碱受体介导的呼吸，泌尿和胃肠系统的各种疾病，以及其它用途。 本发明还涉及制备所公开的化合物的方法，含有所公开的化合物的药物组合物，以及用于治疗通过毒蕈碱受体介导的疾病的方法。 式（I）其中Het：是杂环基或杂芳基X：O，S或NR1，其它取代基如权利要求中所定义。

公开(公告)号：US20090131410A1

公开(公告)日：2009-05-21

申请号：US12089150

申请日：2006-10-05

Applicant: Naresh Kumar ,  Kirandeep Kaur ,  Suman Gupta ,  Anita Chugh ,  Mohammad Salman ,  Raj Kumar Shirumalla ,  Shivani Malhotra

Inventor： Naresh Kumar ,  Kirandeep Kaur ,  Suman Gupta ,  Anita Chugh ,  Mohammad Salman ,  Raj Kumar Shirumalla ,  Shivani Malhotra

IPC: A61K31/55 ,  C07D223/14 ,  A61P3/10

CPC classification number: C07D221/24 ,  C07D405/12 ,  C07D409/12

Abstract: Provided are muscarinic receptor antagonists, which can be useful in treating various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. Also provided are processes for preparing compounds described herein, pharmaceutical compositions thereof, and methods for treating diseases mediated through muscarinic receptors.

Abstract translation: 提供毒蕈碱受体拮抗剂，其可用于治疗通过毒蕈碱受体介导的呼吸，尿和胃肠道系统的各种疾病。 还提供了用于制备本文所述的化合物的方法，其药物组合物，以及用于治疗通过毒蕈碱受体介导的疾病的方法。

公开(公告)号：US20090105221A1

公开(公告)日：2009-04-23

申请号：US11576096

申请日：2005-09-28

Applicant: Mohammad Salman ,  Pakala Kumara Savithru Sarma ,  Arani Pal ,  Anita Chugh ,  Suman Gupta ,  Venkata P. Palle ,  Naresh Kumar ,  Kirandeep Kaur

Inventor： Mohammad Salman ,  Pakala Kumara Savithru Sarma ,  Arani Pal ,  Anita Chugh ,  Suman Gupta ,  Venkata P. Palle ,  Naresh Kumar ,  Kirandeep Kaur

IPC: A61K31/55 ,  C07D223/14 ,  C07D405/12 ,  A61P11/00 ,  A61P1/00

CPC classification number: C07D401/12 ,  C07D221/24 ,  C07D405/06 ,  C07D405/12 ,  C07D409/12

Abstract: This present invention generally relates to muscarinic receptor antagonists of Formula (I), which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the prepration of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors.

Abstract translation: 本发明一般涉及式（I）的毒蕈碱受体拮抗剂，其可用于治疗通过毒蕈碱受体介导的呼吸，泌尿和胃肠系统的各种疾病。 本发明还涉及所述化合物的制备方法，包含所公开的化合物的药物组合物，以及通过毒蕈碱受体介导的疾病的治疗方法。

公开(公告)号：US07378535B2

公开(公告)日：2008-05-27

申请号：US11414552

申请日：2006-05-01

Applicant: Roger Read ,  Naresh Kumar

Inventor： Roger Read ,  Naresh Kumar

IPC: C07D307/58

CPC classification number: C08F20/00 ,  A01N43/08 ,  C07D307/58 ,  C08F24/00

Abstract: The present invention relates to the side chain functionalization of fimbrolides (halogenated 3-alkyl-5-methylene-2(5H)-furanones) and their synthetic analogues, that yields fimbrolides substituted with a halogen, an oxygen or a nitrogen functionality in the alkyl chain, especially fimbrolide alcohols, carboxylate and sulfinate and sulfonate esters, ethers, aldehydes, ketones, acids, amides, nitro derivatives, hydrophobic, hydrophilic and fluorophilic alkyl derivatives and polymers.

Abstract translation: 本发明涉及福滨洛尔（卤代3-烷基-5-亚甲基-2（5H） - 呋喃酮）及其合成类似物的侧链官能化，其产生在烷基中被卤素，氧或氮官能团取代的菲莫拉林 链，特别是福美罗瑞醇，羧酸盐和亚磺酸盐和磺酸酯，醚，醛，酮，酸，酰胺，硝基衍生物，疏水性，亲水和氟化烷基衍生物和聚合物。